Cardiawave is a leading brand dedicated to improving patient care through non-invasive therapies. Founded in 2014, Cardiawave emerged from a collaboration between the academic laboratories Physics for Medicine Paris and Langevin Institute, renowned for their expertise in ultrasound imaging and therapy, and the Georges Pompidou European Hospital, a pioneer in valve disease and cardiac ultrasound imaging. As a member of the national research consortium RHU Stop-AS and the MEDICEN Paris Région competitiveness cluster, Cardiawave has secured impressive funding of over €22 million.

Cardiawave has developed a groundbreaking non-invasive ultrasound therapy (NIUT) medical device specifically designed for the treatment of Calcific Aortic Stenosis (CAS), a prevalent heart valve disease in adults and a leading cause of cardiovascular mortality worldwide. The company obtained approval to conduct clinical studies in France, the Netherlands, and Serbia, demonstrating their commitment to advancing research and expanding treatment options. Cardiawave has garnered numerous awards and honors, recognizing their innovation and contributions to the field.

With a mission to enhance patient care, Cardiawave continues to push boundaries and develop cutting-edge medical devices for non-invasive therapies